CO6731076A2 - Nuevo adyuvante - Google Patents

Nuevo adyuvante

Info

Publication number
CO6731076A2
CO6731076A2 CO13107246A CO13107246A CO6731076A2 CO 6731076 A2 CO6731076 A2 CO 6731076A2 CO 13107246 A CO13107246 A CO 13107246A CO 13107246 A CO13107246 A CO 13107246A CO 6731076 A2 CO6731076 A2 CO 6731076A2
Authority
CO
Colombia
Prior art keywords
new adjuvant
adjuvant
new
antigen
combination
Prior art date
Application number
CO13107246A
Other languages
English (en)
Inventor
Carlos Alonso-Bedate
Manuel Soto-Alvarez
La Fuente Nuria Parody-De
De Coana Suarez Yago Pico
Original Assignee
Leti Sl Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti Sl Lab filed Critical Leti Sl Lab
Publication of CO6731076A2 publication Critical patent/CO6731076A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)

Abstract

La invención se refiere a un nuevo adyuvante y a su uso en combinación con un antígeno.
CO13107246A 2010-11-10 2013-04-29 Nuevo adyuvante CO6731076A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41203410P 2010-11-10 2010-11-10
EP10190705 2010-11-10

Publications (1)

Publication Number Publication Date
CO6731076A2 true CO6731076A2 (es) 2013-08-15

Family

ID=43795122

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13107246A CO6731076A2 (es) 2010-11-10 2013-04-29 Nuevo adyuvante

Country Status (18)

Country Link
US (1) US9187751B2 (es)
EP (1) EP2638062B1 (es)
JP (1) JP5986576B2 (es)
KR (1) KR102010994B1 (es)
CN (1) CN103270048B (es)
AR (1) AR083829A1 (es)
AU (1) AU2011328129B2 (es)
CA (1) CA2817421C (es)
CO (1) CO6731076A2 (es)
EA (1) EA033816B1 (es)
ES (1) ES2676179T3 (es)
HU (1) HUE038386T2 (es)
IL (1) IL226286A0 (es)
MX (1) MX345739B (es)
NZ (1) NZ609952A (es)
PL (1) PL2638062T3 (es)
SG (1) SG190222A1 (es)
WO (1) WO2012062861A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3017305B1 (en) 2013-07-02 2018-04-25 Institut De Recherche Pour Le Developpement Peptides and methods for the detection of leishmaniasis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
CA2256124C (en) * 1998-12-23 2015-06-16 C.B.F. Leti S.A. Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
US6525186B2 (en) * 1998-12-23 2003-02-25 C.B.F. Leti S.A. Chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of L. infantum, useful of serologic diagnosis of canine leishmaniosis and protein obtained
US6458359B1 (en) * 1998-12-23 2002-10-01 C.B.F. Leti S.A. Chimeric gene formed by the dna sequences that encode the antigenic determinants of four proteins of l. infantum and protein encoded by said gene, and pharmacuetical composition useful for preventing and/or treating leishmaniosis in animals or humans
FR2826018B1 (fr) * 2001-06-18 2005-01-07 Pasteur Institut Tunis Gene associe a la virulence du parasite leishmania
EP1450821A1 (en) 2001-12-07 2004-09-01 Intercell AG Immunostimulatory oligodeoxynucleotides
EP1485468A4 (en) * 2002-02-21 2007-01-03 Medimmune Vaccines Inc EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
CN1798762B (zh) 2003-04-23 2010-04-28 马普科技促进协会 效能提高的结核病疫苗
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
RU2380710C2 (ru) 2003-11-05 2010-01-27 К.Б.Ф. Лети, С.Л. Юниперсонал Лечение, диагностика или профилактика лейшманиоза, вызванного различными видами паразитов, кроме вида, из которого получены гистоны, с использованием всех четырех гистонов h2a, h2b, h3 и h4, выделенных из leishmania infantum с использованием вектора, содержащего нуклеотиды, кодирующие указанные гистоны
PT2231700E (pt) 2008-01-18 2014-07-31 Leti S L Unipersonal Lab Vacina que compreende extrato de proteína ribossomal (rpe) e um auxiliar estimulante th1 como opção
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي

Also Published As

Publication number Publication date
MX345739B (es) 2017-02-14
CN103270048B (zh) 2016-11-23
EP2638062A1 (en) 2013-09-18
WO2012062861A1 (en) 2012-05-18
KR102010994B1 (ko) 2019-08-14
IL226286A0 (en) 2013-07-31
JP2014500719A (ja) 2014-01-16
US9187751B2 (en) 2015-11-17
CN103270048A (zh) 2013-08-28
KR20130121863A (ko) 2013-11-06
AU2011328129B2 (en) 2016-08-11
EP2638062B1 (en) 2018-04-25
CA2817421C (en) 2020-04-14
SG190222A1 (en) 2013-06-28
US20140030293A1 (en) 2014-01-30
NZ609952A (en) 2015-05-29
AR083829A1 (es) 2013-03-27
CA2817421A1 (en) 2012-05-18
HUE038386T2 (hu) 2018-10-29
MX2013005222A (es) 2014-04-07
ES2676179T3 (es) 2018-07-17
AU2011328129A1 (en) 2013-05-23
EA033816B1 (ru) 2019-11-28
JP5986576B2 (ja) 2016-09-06
PL2638062T3 (pl) 2018-11-30
EA201390670A1 (ru) 2013-10-30

Similar Documents

Publication Publication Date Title
LTC2635601I2 (lt) Antikūnai prieš il-23
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
ECSP11011557A (es) Mimético de smac
BR112012031232A2 (pt) método, dispositivo e uso
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BR112012002349A2 (pt) composto,e, uso do mesmo
DK2651436T3 (da) Mycobakterie antigen sammensætning.
CO6720984A2 (es) Anticuerpos anti-mesotelina e inmunoconjugados
BR112013010988A2 (pt) composição fluída e uso
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
DK2821415T3 (da) Antistof mod anti-lipoarabinomannan og immunoassay til syrefast bacillær infektion under anvendelse af antistoffet
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
BRPI1007494A2 (pt) composto e uso do mesmo
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
BR112014009476A2 (pt) refletor, iluminador e uso do iluminador
BRPI1011036A2 (pt) uso
UY33856A (es) ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?.
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
BR112013012175A2 (pt) combinação, coadministração, uso e método
BR112013019030A2 (pt) válvula de retenção, e, uso de uma válvula de retenção.
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
CO6731076A2 (es) Nuevo adyuvante